Payment overview · 2025
General Payments
$1,081.82
73 reported records · 13 companies
Healthcare provider profile · identity verified
Rahat Hameed Sheikh, MD
Allopathic & Osteopathic Physicians|Family Medicine · PARIS, IL · NPI 1750488771
Verified facts
What the public records show
CMS Open Payments records show Rahat Hameed Sheikh, MD received $1,081.82 in general payments during 2025 across 73 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $278.47 | 25.7% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $171.69 | 15.9% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.12 | 14.9% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $138.47 | 12.8% | 12 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $68.76 | 6.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.36 | 5.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.44 | 4.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.12 | 3.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.14 | 2.8% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $29.07 | 2.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $28.27 | 2.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.59 | 2.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.32 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,081.82 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $234.37 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $130.39 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $114.82 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.77 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.23 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $68.76 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $59.70 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $56.87 | 7 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $56.87 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $45.44 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.84 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.53 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $31.95 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.14 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $29.07 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $29.07 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $29.07 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $28.27 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $28.27 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.59 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 47 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 363 | 100 |
| Lisinopril | Lisinopril | 335 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 81 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 268 | 65 |
| Omeprazole | Omeprazole | 246 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 235 | 38 |
| Metformin Hcl | Metformin Hcl | 235 | 77 |
| Alprazolam | Alprazolam | 224 | 32 |
| Gabapentin | Gabapentin | 205 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 184 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 49 |
| Losartan Potassium | Losartan Potassium | 160 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 38 |
| Furosemide | Furosemide | 131 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 128 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 40 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 124 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 33 |
| Potassium Chloride | Potassium Chloride | 106 | 25 |
| Clonazepam | Clonazepam | 101 | 20 |
| Simvastatin | Simvastatin | 93 | 26 |
| Montelukast Sodium | Montelukast Sodium | 89 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 25 |
| Lorazepam | Lorazepam | 82 | 19 |
| Tramadol Hcl | Tramadol Hcl | 80 | 12 |
| Prednisone | Prednisone | 79 | 37 |
| Alendronate Sodium | Alendronate Sodium | 76 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 24 |
| Allopurinol | Allopurinol | 73 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 72 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 21 |
| Pregabalin | Pregabalin | 70 | 16 |
| Meloxicam | Meloxicam | 69 | 23 |
| Carvedilol | Carvedilol | 63 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 63 | 20 |
| Ozempic | Semaglutide | 60 | 15 |
| Atenolol | Atenolol | 59 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 13 |
| Famotidine | Famotidine | 49 | 17 |
| Eliquis | Apixaban | 47 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 16 |
| Levofloxacin | Levofloxacin | 45 | 35 |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 20 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 20 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Nystatin | Nystatin | 18 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Finasteride | Finasteride | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,081.82 · 73 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BEXSERO, BEYFORTUS, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Fluad, Flucelvax, Kerendia, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, VYNDAMAX, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error